Moreover, in another cohort of 121 patients also presenting metastatic EGFR-mutated lung cancer with BM and treated by osimertinib, an upfront SRT treatment of all BMs revealed a better OS outcome compared to osimertinib alone (HR = 0.37, 95% CI 0.16–0.87, p = 0.021) [34]. The gene discussed is EGFR; the disease is lung carcinoma.